1. 216. A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of the Beta-lactamase inhibitor Xeruborbactam Alone and in Combination Meropenem in Healthy Adult Subjects. (15th December 2022) Authors: Griffith, David; Roberts, Jason; Wallis, Steven; Hernandez-Mitre, Maria Patricia; Morgan, Elizabeth; Gehrke, Shawnee; Dudley, Michael; Loutit, Jeff Journal: Open forum infectious diseases Issue: Volume 9:(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 217. A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of the Lipopeptide QPX9003 in Healthy Adult Subjects. (15th December 2022) Authors: Griffith, David; Carmeli, Yehuda; Gehrke, Shawnee; Morgan, Elizabeth; Dudley, Michael; Loutit, Jeff Journal: Open forum infectious diseases Issue: Volume 9:(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 218. A Phase 1 Study of the Single-Dose Safety, Tolerability, and Pharmacokinetics of the Beta-lactamase inhibitor Xeruborbactam Administered as the Isobutyryloxymethyl Oral Prodrug to Healthy Adult Subjects. (15th December 2022) Authors: Griffith, David; Roberts, Jason; Wallis, Steven; Hernandez-Mitre, Maria Patricia; Morgan, Elizabeth; Dudley, Michael; Loutit, Jeff Journal: Open forum infectious diseases Issue: Volume 9:(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 338Prevalence, Mortality and Outcomes of Antibiotic Therapy of Multi-Drug Resistant Acinetobacter baumannii. (December 2014) Authors: Lapensee, Kenneth T.; Fan, Weihong; Redell, Mark; Dudley, Michael; Loutit, Jeff Journal: Open forum infectious diseases Issue: Volume 1(2014)Supplement 1 Page Start: S136 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 401A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the Beta-lactamase inhibitor RPX7009 Alone, Meropenem Alone, and both in Combination (Carbavance) TID for 7 days in Healthy Adult Subjects. (December 2014) Authors: Griffith, David; Rubino, Christopher; Loutit, Jeff; Morgan, Elizabeth; White, Dan; Dudley, Michael Journal: Open forum infectious diseases Issue: Volume 1(2014)Supplement 1 Page Start: S154 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. A Real-world Patient Registry for Oritavancin Demonstrates Efficacy and Safety Consistent With the Phase 3 SOLO Program. (19th March 2018) Authors: Redell, Mark; Moeck, Greg; Lucasti, Christopher; Durso, Stephanie; Kennedy, Cynthia; Fusaro, Karen; Loutit, Jeff; Dudley, Michael Journal: Open forum infectious diseases Issue: Volume 5:Number 6(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗